Hairong Huo, PhD, MS

Articles by Hairong Huo, PhD, MS

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia

ByJalpa A. Doshi, PhD,Pengxiang Li, PhD,Hairong Huo, PhD, MS,Amy R. Pettit, PhD,Rishab Kumar,Brendan M. Weiss, MD,Scott F. Huntington, MD, MPH

March 18th 2016

A Medicare claims analysis of patients newly diagnosed with chronic myeloid leukemia revealed that high cost sharing was associated with reduced and/or delayed tyrosine kinase inhibitor initiation under Part D.

Latest Updated Articles

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia
Published: March 18th 2016 | Updated:

Hairong Huo, PhD, MS

Articles by Hairong Huo, PhD, MS

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia

Latest Updated Articles

Trending on AJMC

FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma

IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?

Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD

Guidelines for Bronchiectasis Highlight Multiple Treatment Methods

Radiotherapy Plus Chemo Benefits Certain Patients With DLBCL